Artivion (NYSE:AORT) PT Raised to $30.00 at Needham & Company LLC

Artivion (NYSE:AORT) had its price target lifted by investment analysts at Needham & Company LLC from $25.00 to $30.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 28.59% from the stock’s current price.

Separately, Stifel Nicolaus increased their price objective on Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 16th.

Artivion Trading Down 1.9 %

Shares of NYSE AORT opened at $23.33 on Tuesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. The stock has a market capitalization of $961.20 million, a P/E ratio of -31.11 and a beta of 1.66. Artivion has a 1-year low of $12.16 and a 1-year high of $25.51. The business has a fifty day moving average price of $20.57 and a 200 day moving average price of $18.18.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, May 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The company had revenue of $97.43 million during the quarter, compared to analysts’ expectations of $92.30 million. During the same period last year, the business posted $0.02 earnings per share. Equities research analysts expect that Artivion will post 0.26 EPS for the current fiscal year.

Insider Activity

In other news, SVP Marshall S. Stanton sold 2,183 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total value of $44,511.37. Following the transaction, the senior vice president now owns 83,296 shares in the company, valued at $1,698,405.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, VP Andrew M. Green sold 1,462 shares of Artivion stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $20.00, for a total transaction of $29,240.00. Following the transaction, the vice president now owns 41,121 shares in the company, valued at $822,420. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Marshall S. Stanton sold 2,183 shares of Artivion stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total value of $44,511.37. Following the transaction, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The disclosure for this sale can be found here. Insiders have sold a total of 149,952 shares of company stock worth $2,891,627 over the last quarter. 8.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AORT. GAMMA Investing LLC raised its position in Artivion by 38.6% in the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after purchasing an additional 505 shares during the period. Register Financial Advisors LLC purchased a new stake in Artivion in the first quarter valued at $114,000. Allspring Global Investments Holdings LLC raised its position in Artivion by 291.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after purchasing an additional 4,154 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Artivion by 97.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,322 shares of the company’s stock valued at $126,000 after purchasing an additional 4,099 shares during the period. Finally, Silverleafe Capital Partners LLC purchased a new stake in Artivion in the third quarter valued at $152,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.